Opinion

Video

NCCN Guidelines Revisions and ASCO 2024 Research Outlook

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

Related Videos
John Ostrominski, MD
John Buse, MD, PhD
Christian T. Ruff, MD, MPH
Dr Geoffrey Rutledge
Jason Bellet of Eko Health
Dr Geoffrey Rutledge
3 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo